Verastem, Inc. (VSTM)

Market Cap	74.96M
Revenue (ttm)	n/a
Net Income (ttm)	-105.52M
Shares Out	25.33M
EPS (ttm)	-4.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	845,122
Open	3.000
Previous Close	2.970
Day's Range	2.920 - 3.160
52-Week Range	2.540 - 14.220
Beta	0.19
Analysts	Strong Buy
Price Target	20.21 (+582.77%)
Earnings Date	Aug 6, 2024

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM

Analyst Forecast

According to 7 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $20.21, which is an increase of 582.77% from the latest price.

Price Target

$20.21

(582.77% upside)

Analyst Consensus: Strong Buy